Healthcare Bizdev
HCBD-Pro Services Client Subscribers

HCBD-PRO Services

Query News -

Welcome <Guest> Login
back to News
 
Highmark Inc. announces outcomes-based agreement with Boehringer Ingelheim for Jardiance

Source Highmark Inc.
Published Date 7/10/2018
Jardiance (empagliflozin) agreement marks Highmark's second outcomes-based contract this year

Continuing its efforts to address high prescription drug costs, Highmark Inc. today announced its latest outcomes-based contract with Boehringer Ingelheim for Jardiance® (empagliflozin), an oral medicine indicated to lower blood sugar in adults with type 2 diabetes, and also to reduce the risk of cardiovascular death in adults with type 2 diabetes who have known cardiovascular disease. Jardiance is a product in the Boehringer Ingelheim and Eli Lilly and Company diabetes alliance portfolio. ...
View the entire Highmark Inc. article
    LinkedIn
 
Featured Companies
Highmark Inc.
Pittsburgh, PA
 

Company Representatives Featured
Dominique Buccina
[Media Contact]
Highmark Inc.
Media Contact
 
Ryan Cox
[Director of Clinical Pharmacy Services]
Highmark Inc.
 
Christine Marsh
[Vice President, Business Analysis]
Boehringer Ingelheim Pharmaceuticals Inc.
 
Leilyn Perri
[Corporate Media Relations Director]
Highmark Blue Shield
Media Contact
 
Kayse Reitmeyer
[Pharmaceutical Manufacturer Relations Director]
Highmark Inc.
 
 
back to News
About Us | Purchase Pro | Contact Us

© 2006-2010 Healthcare BizDev, Inc. All rights reserved. Privacy Policy | Legal Conditions